June 02, 2016
A Massachusetts federal judge on Thursday concluded that individual questions of causation and injury outweigh certification of a proposed class of third-party payors accusing Forest Laboratories Inc. in multidistrict litigation of misleading consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression.